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The current outbreak of pandemic influenza (H1N1) 2009 
demonstrates yet again how enigmatic, unpredictable and 
challenging the influenza virus is. First isolated in 1933 by 
Laidlaw, Andrewes and Smith1 and one of the first human 
viruses to be isolated, it has been intensively studied in 
the minutest of details over many decades. Yet in 2009 
this remarkable virus still baffles virologists and perplexes 
epidemiologists with its unpredictability and its penchant for 
upsetting prevailing dogmas.2 
For almost a decade, the global community had been 
anticipating that the avian influenza A (H5N1) virus would be 
responsible for the next pandemic, which should be imminent 
if the 15 - 50-year cycle of pandemics were to hold. This would 
also fit in with influenza A (H5N1) being a new subtype of 
virus to humans, as was the case with previous pandemics – 
H1N1 in 1918, H2N2 in 1957 and H3N2 in 1968. Today, 40 years 
after the last pandemic, it is the novel swine influenza  virus 
that has launched the current pandemic even though it is not a 
new subtype – H1N1 subtype has circulated in humans since 
1977. It is, however, certainly a virus novel to humans, 
antigenically and biologically quite distinct from human H1N1. 
Where has this virus come from, and what does it hold for the 
world and for South Africa in particular? 
Classic swine influenza virus of the H1N1 subtype was 
identified as far back as 1931 as a cause of respiratory disease 
in pigs.1 The virus is endemic in pig herds in North and South 
America, parts of Europe, East Asia and Africa (Kenya). 
Human infections with this virus have been an occupational 
risk resulting in sporadic cases of an influenza-like illness 
but with little or no human-to-human transmission. In 1976, 
however, an outbreak of swine flu in a military camp (Fort Dix, 
New Jersey) was responsible for 230 cases and severe illness in 
some 13 soldiers with 1 death.3 Here there was clear human-
to-human transmission, but the infection mysteriously died 
out. More recently a derivative of the classic swine influenza 
virus was detected. Pigs are susceptible and are frequently 
infected by influenza viruses from birds and humans. It is 
therefore not too surprising that a novel swine influenza virus 
arose as a result of the exchange of genetic material, referred 
to as reassortment, from influenza viruses from swine, avian 
and human sources.4 This triple reassortant swine influenza A 
(H1N1) virus was first detected in human patients in December 
2005 in the USA and, until the present novel influenza A 
(H1N1) outbreak in April 2009, 11 cases of infection had been 
reported, in 10 of which there had been contact with pigs. 
While the clinical presentation resembles human influenza 
illness in many respects, some important differences have 
been described. The disease was mainly found in children and 
young adults (median age 10 years), the incubation period was 
somewhat longer than human influenza (median 3.5 days), and 
unusual clinical signs were described in about a quarter of the 
patients, who presented with gastro-intestinal symptoms of 
vomiting and diarrhoea.
The current pandemic influenza (H1N1) 2009 virus 
arose from a subsequent reassortment event from the triple 
reassortant swine influenza A (H1N1) virus.5 The latter virus 
contains 5 genes from the classic swine virus (haemagglutinin 
HA, nucleoprotein NP, neuraminidase NA, matrix M, and non-
structural NS), 2 genes from avian influenza virus (polymerase 
PB2 and PA) and a single gene from human influenza virus 
(polymerase PB1). In the case of pandemic influenza (H1N1) 
virus, the NA and M swine genes, which were of North 
American origin, were replaced by genes of Eurasian origin. 
The effect has been to create a novel reassortant virus able 
to transmit efficiently from human to human and spreading 
within a matter of 6 weeks throughout the world. Early in June 
the WHO declared a global pandemic. The virus is now well 
established in the human population – the 100 000 mark having 
been passed in mid-July, although the true tally is greatly in 
excess of this. Fortunately the disease has been relatively mild 
in the majority of cases – no more serious than the regular 
annual seasonal influenza. What is different is the greater 
involvement of younger individuals (median of 10 - 20 years 
of age and relative sparing of older persons), a pattern quite 
unlike seasonal influenza and more akin to past pandemics. 
Risk factors for severe disease include those conventionally 
described for seasonal influenza (with the exception of the 
elderly) but now also including obesity and pregnancy.
Well over 100 laboratory-confirmed cases have been detected 
in South Africa as at mid-July and therefore, as has been 
internationally recommended, routine testing of all suspect 
cases as well as daily number counting has been stopped as 
this would add very little value in managing the outbreak, 
which has undoubtedly spread well beyond the numbers 
confirmed through laboratory testing. The winter season could 
well promote significant spread of the virus, as it does for 
seasonal influenza, further aggravated by the crowded and 
inadequately ventilated living conditions of a large proportion 
of our population. Underlying immunosuppressive diseases 
such as HIV and TB are clearly also aggravating factors – again 
focusing on the young adult population. The effect of 
immunosuppression on viral excretion and the epidemiological 
consequences will also need to be investigated. Influenza is an 
infection of very high transmissibility and very little can be 
done to prevent the virus spreading through a non-immune 
population. It is hoped that an effective vaccine will become 
available for widespread use by the end of the year. For the 
individual, personal hygiene practices such as cough and 
sneeze etiquette, frequent hand washing and social distancing 
will reduce the chances of transmission.
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Given the notorious unpredictability of influenza virus, 
the long-term future of the pandemic cannot be forecast.2 
Unlike previous pandemics, pandemic influenza (H1N1) 2009, 
although not a new subtype of influenza virus, does represent 
a virus that is new to the human population both antigenically 
and biologically. The extent of cross-protection from prior 
exposure to human H1N1 influenza, either from past natural 
infection or from vaccination, still needs to be defined although 
the relative sparing of older individuals probably does 
represent some degree of cross-protection.
At present, oseltamivir remains the drug of choice for 
both treatment and post-exposure prophylaxis in high-risk 
persons, although the clinical efficacy for pandemic influenza 
(H1N1) has not yet been adequately established.5 The virus 
remains sensitive to both oseltamivir and zanamivir; however, 
the explosion of resistance to oseltamivir by H1N1 human 
influenza virus over the past 2 years has taken virologists 
aback – in South Africa all 2008 H1N1 isolates tested highly 
resistant to the drug.6
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